Caliway's CBL-514 Phase 2 Study (CBL-0202) Accepted for Publication in the Aesthetic Surgery Journal
Advancing Scientific Recognition in Non-Surgical Fat Reduction Caliway's CBL-514 Phase 2 study (CBL-0202) has been accepted for publication in Aesthetic Surgery Journal (ASJ), the top-ranked journal in aesthetic medicine and plastic surgery....
Caliway Announces CBL-514 Second Phase 2b Study Results (CBL-0205) Met Endpoints
CBL-514, the world's first investigational drug for large-area localized fat reduction, has demonstrated significant efficacy in its second and the last Phase 2b study (CBL-0205) before Phase 3. 54.2% of participants in the CBL-514 group achieved at...
Caliway to Present CBL-514 Phase 2b Study Results for Subcutaneous Fat Reduction at IMCAS 2025 in Paris
The findings from the CBL-0204 Phase 2b clinical trial have been selected for presentation at IMCAS, the premier global congress in aesthetic medicine. The data will be highlighted in both the 2025 focus session on advances in fat reduction...